Literature DB >> 6829514

Newborn sickle cell screening. Benefits and burdens realized.

P T Rowley, D J Huntzinger.   

Abstract

Seventeen newborns identified by state-mandated screening as having sickle cell disease or homozygous hemoglobin C disease were followed up through interviews of their physicians and their parents to assess benefits and burdens received by the families. Many parents had provided proper care for their children (12/17) and pneumococcal prophylaxis had been given (6/14). However, some parents did not understand the recurrence risk (3/11) and for others genetic counseling may have threatened the parental relationship by focusing attention on the identity of the father (3/11). Deriving the maximum benefit from newborn sickle cell screening will require a better understanding on the part of physicians of the differential diagnosis, treatment, and inheritance of sickle cell disease and guidance regarding comprehensive counseling of families. In the meantime, states mandating such screening need to provide individual case follow-up.

Entities:  

Mesh:

Year:  1983        PMID: 6829514     DOI: 10.1001/archpedi.1983.02140300023007

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  4 in total

1.  Costing model for neonatal screening and diagnosis of haemoglobinopathies.

Authors:  E K Cronin; C Normand; J S Henthorn; M Hickman; S C Davies
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-11       Impact factor: 5.747

2.  Assessment of care of children with sickle cell disease: implications for neonatal screening programmes.

Authors:  R I Milne
Journal:  BMJ       Date:  1990-02-10

3.  The University of Florida sickle cell screening program for neonates: design and results.

Authors:  R V Gardner; A Keitt
Journal:  J Natl Med Assoc       Date:  1988-03       Impact factor: 1.798

Review 4.  Intervention strategies for children: a research agenda.

Authors:  K J Roghmann
Journal:  Health Serv Res       Date:  1985-02       Impact factor: 3.402

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.